exalt® is a DeepTech spin-off from the Medical University of Vienna and develops a functional precision oncology test that determines the most effective therapy for each cancer patient. By testing living tumor cells ex vivo, our technology identifies effective treatments on tumor cells while sparing healthy cells. exalt® envisions a future where therapy decisions are guided by real patient response rather than probability, making personalized, evidence-based cancer care the global standard. We demonstrated a clear clinical benefit for late-stage cancer patients, and exalt® empowers oncologists with actionable insights and transforms oncology into a precise, patient-specific science; building a new paradigm shift in cancer care.